21-036 - AALL1631 - Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaStatus: open
|AALL1631 - International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones|
Treatment for Pediatric Oncology - lymphoblastic leukemia
To compare disease free survival (DFS) of Standard Risk (SR) pediatric Ph+ ALL treated with continuous imatinib combined with either a high-risk COG ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
SponsorsThis trial is sponsored by Children's Oncology Group.
Interested in Clinical Trial?
Providers Associated With This Trial
- Hamayun Imran, M.D.Pediatric Hematologist/OncologistProfessor of Pediatrics
- Chibuzo Ilonze, M.D., M.P.H.Pediatric Hematologist/OncologistAssistant Professor of Pediatric Hematology/Oncology
- Preethi Marri, M.D.Pediatric Hematology and OncologyAssistant Professor of Pediatrics
- Felicia L. Wilson, M.D.Pediatric Hematologist/OncologistProfessor of Pediatrics